EU-PACT
A pharmacogenomic approach to coumarin anticoagulant therapy
| Coordinatore | UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.uu.nl/faculty/science/EN/organisation/depts/pharmaceuticalsciences/research/pp/projects/eupact/Pages/default.aspx |
| Totale costo | 3˙575˙385 € |
| EC contributo | 2˙544˙891 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-10-01 - 2013-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
NL (UTRECHT) | coordinator | 658˙185.00 |
| 2 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 488˙072.00 |
| 3 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 388˙696.00 |
| 4 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 309˙541.00 |
| 5 |
DEMOCRITUS UNIVERSITY OF THRACE
Organization address
address: PANEPISTIMIOUPOLI contact info |
EL (KOMOTINI) | participant | 224˙904.00 |
| 6 |
LGC LIMITED
Organization address
address: QUEENS ROAD contact info |
UK (TEDDINGTON) | participant | 161˙452.00 |
| 7 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 154˙858.00 |
| 8 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 73˙680.00 |
| 9 |
ALLGEMEIN OFFENTLICHES KRANKENHAUS DER ELISABETHINEN
Organization address
address: FADINGERSTRASSE 1 contact info |
AT (LINZ) | participant | 54˙810.00 |
| 10 |
ERASMUS UNIVERSITEIT ROTTERDAM
Organization address
address: BURGEMEESTER OUDLAAN 50 contact info |
NL (ROTTERDAM) | participant | 19˙182.90 |
| 11 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 11˙510.10 |
| 12 |
UNIVERSITE PARIS-SUD
Organization address
address: RUE GEORGES CLEMENCEAU 15 contact info |
FR (ORSAY) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The effectiveness of treatment with oral anticoagulants in the prevention of thrombotic disorders is well established, but these drugs are potentially dangerous because of their narrow therapeutic index. In Europe three coumarins are used: warfarin, acenocoumarol, and phenprocoumon. Genetic factors that have been recently demonstrated to change the pharmacokinetics and pharmacodynamics of coumarins are the presence of polymorphisms in the genes encoding for CYP2C9 and VKOR (vitamin K epoxide reductase complex). Polymorphisms in these genes are associated with increased risk for severe overanticoagulation and bleedings. A clinical trial will be performed in seven European countries to determine whether knowledge of the genotype of patients at the start of coumarin treatment will increase the safety of use of these compounds and whether such gene testing is cost-effective. Patients will be randomized to receive treatment with a coumarin either dosed with an algorithm that does not include information on their genotype, or with an algorithm that does contain this information. The primary outcome will be time within therapeutic INR range. Secondary outcomes include INR>4 and bleedings.'